A review of nonsurgical facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1% in periorbital revitalization.
oxymetazoline
periorbital rejuvenation
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
13 Feb 2024
13 Feb 2024
Historique:
revised:
20
09
2023
received:
20
07
2023
accepted:
22
09
2023
medline:
13
2
2024
pubmed:
13
2
2024
entrez:
13
2
2024
Statut:
aheadofprint
Résumé
The demand for nonsurgical facial rejuvenation options is growing, yet the periorbital region remains an area of relative unmet need. This review explores nonsurgical options for facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating age-related blepharoptosis as part of periorbital rejuvenation. Advisors experienced in facial rejuvenation met to discuss existing literature on the upper face and periorbital rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating facial aging. An array of nonsurgical options exist to address the signs of aging, including minimally invasive treatments, such as botulinum toxin injections and dermal fillers, and noninvasive therapy, such as lasers, chemical peels, and microdermabrasion. However, treating age-related ptosis in periorbital rejuvenation is mainly addressed surgically. The newly approved α-adrenergic receptor agonist oxymetazoline hydrochloride ophthalmic solution, 0.1%, provides a novel non-interventional approach to blepharoptosis. Facial rejuvenation is highly sought-after in this post-pandemic era. Each nonsurgical treatment option has its advantages and drawbacks. A patient-centered approach is necessary to select the appropriate procedure considering the patient's concerns and aesthetic sensibilities. The eyes are an area of primary concern for patients, yet surgery is the gold standard for treating ptosis. Oxymetazoline hydrochloride ophthalmic solution, 0.1%, is a safe and effective nonsurgical treatment for blepharoptosis.
Sections du résumé
BACKGROUND
BACKGROUND
The demand for nonsurgical facial rejuvenation options is growing, yet the periorbital region remains an area of relative unmet need. This review explores nonsurgical options for facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating age-related blepharoptosis as part of periorbital rejuvenation.
METHODS
METHODS
Advisors experienced in facial rejuvenation met to discuss existing literature on the upper face and periorbital rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating facial aging.
RESULTS
RESULTS
An array of nonsurgical options exist to address the signs of aging, including minimally invasive treatments, such as botulinum toxin injections and dermal fillers, and noninvasive therapy, such as lasers, chemical peels, and microdermabrasion. However, treating age-related ptosis in periorbital rejuvenation is mainly addressed surgically. The newly approved α-adrenergic receptor agonist oxymetazoline hydrochloride ophthalmic solution, 0.1%, provides a novel non-interventional approach to blepharoptosis.
CONCLUSIONS
CONCLUSIONS
Facial rejuvenation is highly sought-after in this post-pandemic era. Each nonsurgical treatment option has its advantages and drawbacks. A patient-centered approach is necessary to select the appropriate procedure considering the patient's concerns and aesthetic sensibilities. The eyes are an area of primary concern for patients, yet surgery is the gold standard for treating ptosis. Oxymetazoline hydrochloride ophthalmic solution, 0.1%, is a safe and effective nonsurgical treatment for blepharoptosis.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : RVL Pharmaceuticals
Informations de copyright
© 2024 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
Zhang S, Duan E. Fighting against skin aging: the way from bench to bedside. Cell Transplant. 2018;27(5):729-738. doi:10.1177/0963689717725755
Li K, Meng F, Li YR, et al. Application of nonsurgical modalities in improving facial aging. Int J Dent. 2022;2022:8332631. doi:10.1155/2022/8332631
Michaud T, Gassia V, Belhaouari L. Facial dynamics and emotional expressions in facial aging treatments. J Cosmet Dermatol. 2015;14(1):9-21. doi:10.1111/jocd.12128
Neimkin MG, Holds JB. Evaluation of eyelid function and aesthetics. Facial Plast Surg Clin North Am. 2016;24(2):97-106. doi:10.1016/j.fsc.2015.12.002
Sieber DA, Kenkel JM. Noninvasive methods for lower facial rejuvenation. Clin Plast Surg. 2018;45(4):571-584. doi:10.1016/j.cps.2018.06.003
Choudhury S, Baker MR, Chatterjee S, Kumar H. Botulinum toxin: an update on pharmacology and newer products in development. Toxins (Basel). 2021;13(1):58. doi:10.3390/toxins13010058
Hallett M. Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them. Toxicon. 2015;107(Pt A):64-67. doi:10.1016/j.toxicon.2015.07.013
Sundaram H, Signorini M, Liew S, et al. Global aesthetics consensus: botulinum toxin type A-evidence-based review, emerging concepts, and consensus recomincluding updates on complications. Plast Reconstr Surg. 2016;137(3):518e-529e. doi:10.1097/01.prs.0000475758.63709.23
Robati RM, Moeineddin F, Almasi-Nasrabadi M. The risk of skin necrosis following hyaluronic acid filler injection in patients with a history of cosmetic rhinoplasty. Aesthet Surg J. 2018;38(8):883-888. doi:10.1093/asj/sjy005
Kalmanson OA, Misch ES, Terella A. Hyaluronic acid fillers may be longer-lasting than previously described: a case report of delayed filler-associated facial cellulitis. JPRAS Open. 2022;33:37-41. doi:10.1016/j.jpra.2022.05.011
Loghem JV, Yutskovskaya YA, Philip WW. Calcium hydroxylapatite: over a decade of clinical experience. J Clin Aesthet Dermatol. 2015;8(1):38-49.
Fitzgerald R, Bass LM, Goldberg DJ, Graivier MH, Lorenc ZP. Physiochemical characteristics of Poly-L-lactic acid (PLLA). Aesthet Surg J. 2018;38(suppl_1):S13-s17. doi:10.1093/asj/sjy012
Groen JW, Krastev TK, Hommes J, Wilschut JA, Ritt M, van der Hulst R. Autologous fat transfer for facial rejuvenation: a systematic review on technique, efficacy, and satisfaction. Plast Reconstr Surg Glob Open. 2017;5(12):e1606. doi:10.1097/gox.0000000000001606
Solomon P, Ng CL, Kerzner J, Rival R. Facial soft tissue augmentation with Bellafill: a review of 4 years of clinical experience in 212 patients. Plast Surg (Oakv). 2021;29(2):98-102. doi:10.1177/2292550320933675
Heidari Beigvand H, Razzaghi M, Rostami-Nejad M, et al. Assessment of laser effects on skin rejuvenation. J Lasers Med Sci. 2020;11(2):212-219. doi:10.34172/jlms.2020.35
Meaike JD, Agrawal N, Chang D, Lee EI, Nigro MG. Noninvasive facial rejuvenation. Part 3: physician-directed-lasers, chemical peels, and other noninvasive modalities. Semin Plast Surg. 2016;30(3):143-150. doi:10.1055/s-0036-1584818
Lukac M, Zorman A, Lukac N, Perhavec T, Tasic B. Characteristics of non-ablative resurfacing of soft tissues by repetitive Er:YAG laser pulse irradiation. Lasers Surg Med. 2021;53(9):1266-1278. doi:10.1002/lsm.23402
Avci P, Gupta A, Sadasivam M, et al. Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin Cutan Med Surg. 2013;32(1):41-52.
American Society of Plastic Surgeons. Plastic surgery statistics report. 2020. Accessed March 26, 2023https://www.plasticsurgery.org/news/plastic-surgery-statistics
Prantl L, Heidekrueger PI, Broer PN, Knoll S, Thiha A, Gründl M. Female eye attractiveness - where beauty meets science. J Craniomaxillofac Surg. 2019;47(1):73-79. doi:10.1016/j.jcms.2018.05.034
Przylipiak M, Przylipiak J, Terlikowski R, Lubowicka E, Chrostek L, Przylipiak A. Impact of face proportions on face attractiveness. J Cosmet Dermatol. 2018;17(6):954-959. doi:10.1111/jocd.12783
Vaca EE, Bricker JT, Helenowski I, Park ED, Alghoul MS. Identifying aesthetically appealing upper eyelid topographic proportions. Aesthet Surg J. 2019;39(8):824-834. doi:10.1093/asj/sjz014
Slonim CB, Foster S, Jaros M, et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020;138(11):1168-1175. doi:10.1001/jamaophthalmol.2020.3812
Nestor MS, Han H, Gade A, Fischer D, Saban Y, Polselli R. Botulinum toxin-induced blepharoptosis: anatomy, etiology, prevention, and therapeutic options. J Cosmet Dermatol. 2021;20(10):3133-3146. doi:10.1111/jocd.14361
Bacharach J, Wirta DL, Smyth-Medina R, et al. Rapid and sustained eyelid elevation in acquired blepharoptosis with oxymetazoline 0.1%: randomized phase 3 trial results. Clin Ophthalmol. 2021;15:2743-2751. doi:10.2147/opth.S306155
Shaw LT, Phelps PO. The basics of brow ptosis. Dis Mon. 2020;66(10):101038. doi:10.1016/j.disamonth.2020.101038
Wirta DL, Korenfeld MS, Foster S, et al. Safety of once-daily oxymetazoline HCl ophthalmic solution, 0.1% in patients with acquired blepharoptosis: results from four randomized, double-masked clinical trials. Clin Ophthalmol. 2021;15:4035-4048. doi:10.2147/opth.S322326
McAuliffe-Curtin D, Buckley C. Review of alpha adrenoceptor function in the eye. Eye (Lond). 1989;3(Pt 4):472-476. doi:10.1038/eye.1989.71
Surgeons. ASoP. Inaugural ASPS insights and trends report: cosmetic surgery. 2022 Accessed March 27, 2023. https://www.plasticsurgery.org/
Society TA. Aesthetic Plastic Surgery National Databank Statistics 2020-2021. 2021. Accessed March 27, 2023. https://www.theaestheticsociety.org/media/procedural-statistics
Oranges CM, Gohritz A, Haug M, Harder Y, Schaefer DJ. Universal and ethnic-specific considerations on facial rejuvenation: where do you inject your fillers? Plast Reconstr Surg Glob Open. 2016;4(8):e842. doi:10.1097/gox.0000000000001010
Rahrovan S, Fanian F, Mehryan P, Humbert P, Firooz A. Male versus female skin: what dermatologists and cosmeticians should know. Int J Womens Dermatol. 2018;4(3):122-130. doi:10.1016/j.ijwd.2018.03.002